Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354659 | 0.95 | TDP1 (0.38) | OXTRAVPR1ATP53GAATDP1 | |
| SCHEMBL353452 | 0.82 | MEN1 (0.37) | PDE1APDE1BPDE3BPDE1CPDE3A | |
| SCHEMBL354656 | 0.80 | MEN1 (0.44) | LPAR1TP53TDP1 | |
| SCHEMBL355460 | 0.79 | LMNA (0.37) | LPAR1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL353665 | 0.77 | BCL2 (0.37) | PDE1APDE1BPDE3BPDE1CPDE3A | |
| SCHEMBL355205 | 0.77 | SMN1; SMN2 (0.40) | TDP1 | |
| SCHEMBL353822 | 0.76 | BCL2 (0.40) | TDP1 | |
| SCHEMBL353540 | 0.74 | BCL2 (0.36) | TP53PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL354841 | 0.73 | TAS1R3 (0.37) | TP53PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL353909 | 0.71 | MEN1 (0.43) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | OXTR 2095/4885AVPR1A 4429/4885LPAR1 2280/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | OXTR 2164/4885AVPR1A 4446/4885LPAR1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.